Through the agreement, Forward Pharma will provide Biogen an irrevocable license to its intellectual property.
The two drugmakers are involved in ongoing disputes over patents for dimethyl fumarate — the main ingredient in Biogen’s MS drug Tecfidera, which earned about $4 billion in sales for 2016. The licensing agreement does not resolve these disputes.
Biogen may owe Forward Pharma future royalty payments on Tecfidera if its patents are ruled invalid against Forward Pharma’s patents.
More articles on supply chain:
Washington, D.C.-area hospitals desperate for blood donations ahead of inauguration
Target invests in supply chain tech startup
4 ways the FDA is working to boost diversity in clinical trials
